PLK1 and diffuse large B-cell lymphoma: Such factors, along with preliminary indications of PLK1 inhibitor activity in lymphoid malignancies [20, 21], raised the possibility that a PLK1/HDAC inhibitory strategy could be effective against DLBCL and related NHL cell types.